Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by jts115on Sep 27, 2013 2:04am
9548 Views
Post# 21772082

I would be willing participate in a class action lawsuit

I would be willing participate in a class action lawsuitI own ~100,000 shares but I don't know if the litigation would be worth it. What I think you could get them on is transactions that don't fall within arms length (without acknowledgement) and breach of fiduciary duty. I think an obvious breach was that this guy below worked for quetzal then he left and the company sold its guatemalan assets at a lowball price back to LAR (where Realini worked) and within weeks sold them at fair value with drill carries and all to Citation Resources (ASX traded) for a whole lot more.

here is the email I sent a few months back to Canadian Anti Fraud center noting my inquiries (note: they didn't respond, probably need to consult a lawyer to get something done):

To Whom It May Concern,

I believe the management of Canadian Venture Exchange traded Santa Maria Petroleum (Formerly Quetzal Energy) has misled investors and conducted a number of non-arms length transactions that have enriched the company's executives at the cost of shareholders.
-Most notably the company invested tens of millions of dollars in Guatemalan properties only to make a distressed sale of the properties for ~1.5M$ (https://www.marketwire.com/press-release/quetzal-energy-divests-guatemala-operations-tsx-venture-qei-1611156.htm).
-The acquiring company was said to be SGS acquisition corp, a vehicle for Latin American Resources (https://www.latinamericanresources.com/our-team.html). The president and CEO of this vehicle was a former Quetzal executive, Michael Realini.
-In the span of only months, the asset was farmed out for dramatically better terms to what has become Citation Resources (a small ASX traded company: https://www.citation.net.au)
There are a number of other potential red flags for the company:
-Management (Ron MacMicken, Gerry Feldman, et el) has broad involvement across a number of other energy investment entities as well as a history of participating in reverse mergers and other sketchy business combinations between such entities.
-The company's executives pays themselves excessively, Santa Maria petroleum has a market cap of approximately 3Mil.$ while salaries and compensation last year, I believe, exceeded 2 Mil.$
-Excessive change in control provisions
All in all, a lot of the management's conduct has been unacceptable and without proper disclosure to shareholders. Many of these offenses are likely, completely legal. However, as a shareholder, I would ask that the appropriate authorities look into potential violations in disclosing this string of sales across parties. I would prefer for this request to remain anonymous, thank you for your help.
Bullboard Posts